in six patients with advanced parkinson 's disease ( pd ) , we have characterized the clinical responses and serum levels of dopa and 3-o-methyldopa in response to continuous i.v. , nasogastroduodenal ( ngd ) , and oral ( p.o . ) administration of l-dopa solution with concomitant suppression of peripheral decarboxylase activity by carbidopa .
C0030567
parkinson 's disease
C0006982
carbidopa